Parvovirus B19, often referred to as the B19 virus, is a seasonal respiratory viral illness that is transmitted through respiratory secretions from an infected individual’s sneezes or coughs, their blood or blood products, or through vertical transmission from a pregnant woman to her baby.
Common symptoms include joint pain in adults and slapped cheek rash in kids. In persons with weakened immune systems and blood disorders, infection can lead to a low blood count. The disease may also heighten the risk of miscarriage early in pregnancy.
Earlier in August, the CDC issued an advisory on the increase in cases of the disease after it received reports of positive lab tests and complications related to the illness.
Now three separate studies have noted increased B19 virus infections in commercial laboratories in the United States. In one of the studies, investigators explored the increase in B19 test positivity from levels recorded during the 2018/19 respiratory illness seasons.
They focused on identifying immunoglobulin M antibodies, which are markers of an infection, in clinical specimens obtained from 359,445 kids and adults. This is in addition to carrying out nucleic acid amplification tests in plasma from over 1000 donor pools monthly.
They found that by spring 2024, the percentage of immunoglobulin M-positive specimens had risen to 9.9%, a significant increase from the 2018 and 2019 peaks of 3.8% and 5.1%. The prevalence of the virus in nucleic acid amplification tests also increased to 20%, a substantial surge from the peaks of 2018 and 2019 of 6.7% and 7.3%.
In their report, the researchers explained that increased positivity of the B19 virus in both healthy plasma donors and clinical specimens indicated higher community transmission. This, they posited, could be because of reduced B19 transmission during the coronavirus pandemic because of measures imposed to mitigate the spread of Covid-19 which, in turn, resulted in more individuals becoming susceptible to B19.
The second study recorded five cases in pregnant women in the state of Minnesota, with researchers revealing that one patient had a miscarriage at twenty weeks while some fetuses developed severe anemia.
The third study revealed that the infection has been observed in teens and kids with sickle cell anemia in Georgia. The researchers involved emphasized the need to monitor children with sickle cell and B19 for complications, noting that early red blood cell transfusion could prevent severe outcomes.
Overall, the researchers involved in all studies encourage healthcare providers to promote measures preventing infection while remaining hypervigilant for evidence of severe swelling or signs of decreased fetal movement when caring for pregnant individuals, as this could be linked to B19.
As more infectious diseases emerge and re-emerge, there is a growing need for companies like Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to ramp up their R&D programs so that viable immune therapies targeting many of these infectious diseases can be readily available to the vulnerable populations that need these treatments.
NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
Enormous resources are being channeled into studying different ways to support the immune system in its fight…
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…
David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers,…
Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…
High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…